Abbott Laboratories (ABT) Stock Price: $91.25+0.75 (+0.83%)
The total return cagr for Abbott Laboratories (ABT) stock is -30.21% over the past 12 months. The 3 year average growth rate is -1.58% and the 5 year cagr is -1.67%. Total return includes dividends reinvested.
The closing share price for Abbott Laboratories (ABT) stock was $91.25 for Tuesday, June 9, 2026, up +0.83% from the previous day.
ABT Price Chart
ABT Key Metrics
See All MetricsABT Earnings Preview
Next Earnings Date
Jul 16, 2026
37 days away
EPS Estimate
1.28
Revenue Est.
$12.54B
Last Quarter Results
EPS
$1.15
vs Estimate
$1.15
Revenue
$11.16B
vs Estimate
$11.00B
ABT Analyst Ratings
Consensus Rating
Based on 24 analysts
Average Price Target
$117.29
+28.5% upside
Low
$92.00
Current
$91.25
High
$135.00
ABT Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $1.29 | N/A | 10 |
| Q2 2027 | N/A | $1.44 | N/A | 6 |
| Q3 2027 | N/A | $1.58 | N/A | 7 |
| Q4 2027 | N/A | $1.74 | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $6.05 | N/A | 15 |
| FY 2028 | N/A | $6.75 | N/A | 9 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $12.78B | N/A | 10 |
| Q2 2027 | N/A | $13.50B | N/A | 6 |
| Q3 2027 | N/A | $14.11B | N/A | 7 |
| Q4 2027 | N/A | $14.54B | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $54.94B | N/A | 15 |
| FY 2028 | N/A | $58.93B | N/A | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
ABT Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1ABT | $158.94B | $91.25 | +0.83% | -30.21% | -1.67% | +10.97% |
ABT Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford